# China Pharma Desk > Same-day English briefs and analysis on China’s pharma industry—regulation, deals, and market access—for industry readers worldwide. Public Ghost content for AI and LLM tooling. Use `/llms-full.txt` for consolidated page and post context. Append `.md` to any post or page URL to get the content in Markdown (for example, `/example-post.md`). ## Pages - [About & Editorial Policy](https://chinapharmadesk.com/about.md) - Editorial scope, primary-source verification rules, AI-use transparency, and contact details for China Pharma Desk. - [China Pharma Glossary: Regulatory, NRDL, VBP & 18A Terms](https://chinapharmadesk.com/china-pharma-glossary.md) - Plain-English reference guide to China’s pharmaceutical institutions and rules: NMPA, CDE, Class 1 drugs, NRDL, VBP, Dual-Channel pharmacies, DRG/DIP, and HKEX 18A. - [China Pharma Intelligence Guide: Regulation, NRDL, VBP & Biotech Deals](https://chinapharmadesk.com/start-here.md) - Structured entry guide to China's biopharma primary disclosures, NMPA/CDE approvals, NRDL reimbursement, provincial VBP tenders, HKEX 18A filings, and Markdown/llms.txt endpoints. ## Posts - [Boan says nivolumab biosimilar BA1104 met its China Phase 3 endpoint](https://chinapharmadesk.com/boan-ba1104-nivolumab-phase3.md) - Shandong Boan Biotechnology (HKEX: 06955) said on Nov 17, 2026 that BA1104 (LY01015, nivolumab) met the primary endpoint of China Phase 3 trial NCT06022861. The registry still lists the study as active, not recruiting. - [IMPACT says the EU approved senaparib while EMA still shows only a September opinion](https://chinapharmadesk.com/impact-senaparib-eu-approval.md) - IMPACT Therapeutics (HKEX: 07630) said on Nov 17, 2026 that the European Commission approved senaparib (Sepalna, EMEA/H/C/006708). EMA's page still shows only the Sept 17 CHMP opinion. - [CMDE tells Class III device makers where to send trial-protocol questions](https://chinapharmadesk.com/china-device-trial-protocol-consultation.md) - CMDE's Nov 17, 2026 notice tells overseas Class III device applicants to email CMDE and caps ordinary products at two protocol consultations, ahead of the Jan 1, 2027 start under NMPA Notice No. 40. - [J&J to buy Ollin for $2.2 billion upfront, adding Innovent-origin IBI324](https://chinapharmadesk.com/jnj-ollin-innovent-ibi324-acquisition.md) - J&J (NYSE: JNJ) agreed on Nov 16, 2026 to buy Ollin for $2.2 billion upfront, adding Innovent Biologics' (HKEX: 01801) IBI324/OLN324; Innovent's proceeds remain unquantified. - [FDA rejects Summit and Akeso's ivonescimab on survival, exposing China's cross-border trial gap](https://chinapharmadesk.com/akeso-summit-ivonescimab-fda-crl.md) - U.S. FDA issued a Nov 15, 2026 Complete Response Letter to Summit (NASDAQ: SMMT) and Akeso (HKEX: 09926) for PD-1 x VEGF bispecific ivonescimab (AK112) over missed primary overall survival in HARMONi. - [China's 2026 dual-list overhaul puts 51 Class 1 drugs into NRDL, cuts prices on high-cost therapies](https://chinapharmadesk.com/china-2026-nrdl-commercial-list-bridge.md) - NHSA Notice No. 29 of 2026 adds 107 drugs (51 Class 1) to basic NRDL and expands the commercial list to 28 from Jan 1, 2027, cutting 60%+ of candidates at expert review and delisting four non-renewed drugs. - [Seven weeks after EC revocation, EMA's CHMP backs Hansoh's Aumseqa alongside Innovent's sintilimab](https://chinapharmadesk.com/hansoh-aumolertinib-innovent-sintilimab-chmp.md) - Hansoh Pharmaceutical (HKEX: 03692) disclosed on Nov 15, 2026 that EMA's CHMP backed Aumseqa (aumolertinib, EMEA/H/C/007167) on Nov 12 after a Sept revocation, alongside Innovent's (HKEX: 01801) Zybrivo. - [Windward Bio's $225 million Nasdaq debut tests China's equity-linked respiratory NewCo model](https://chinapharmadesk.com/windward-bio-ipo-kelun-harbour-qyuns.md) - Windward Bio (NASDAQ: WWB) priced a $175 million IPO and $50 million Sanofi placement on Nov 12, 2026, putting Kelun-Biotech (06990.HK), Harbour BioMed (02142.HK), and Qyuns (02509.HK) assets in public hands. - [Court dismisses WuXi AppTec's 1260H lawsuit after the delisting; Dec 18 OMB risk remains](https://chinapharmadesk.com/wuxi-apptec-1260h-removal-omb-deadline.md) - WuXi AppTec (HKEX: 02359; SSE: 603259) said a U.S. court approved dismissal of its Section 1260H lawsuit on Nov 16, 2026, after a DoD removal effective Nov 10. OMB's Dec 18 BIOSECURE review remains open. - [China Pharma Weekly Ledger (Nov 9–15, 2026): JW placement, Chipscreen IND, Jiuzhitang Ph2b & FDA 483 FOIA archive](https://chinapharmadesk.com/china-pharma-tracker-2026-11-15.md) - Structured Nov 9-15, 2026 ledger covering JW Therapeutics (02126.HK) HK$160M placement, Chipscreen (688321.SS) CS231295 IND, Jiuzhitang (000989.SZ) Ph2b, Yiling (002603.SZ) approval, and FDA 483 FOIA releases. - [China's 2026 NRDL moves relma-cel into basic insurance. The CAR-T divide remains.](https://chinapharmadesk.com/china-nrdl-relma-cel-cart-payment.md) - NHSA Notice No. 29 of 2026 adds JW Therapeutics (HKEX: 02126) relmacabtagene autoleucel to basic insurance from January 2027, with defined lymphoma restrictions and hospital-access steps. - [Tong Ren Tang revives Tianjin acquisition: the price of buying hospital access](https://chinapharmadesk.com/tongrentang-tianjin-acquisition-cash.md) - Beijing Tong Ren Tang (SSE: 600085) proposes RMB 2.4438 billion for 60% of Tianjin Tongrentang in Announcement 2026-036, reviving a deferred parent-to-listed-company transfer. - [Zai's ZL-1503 supports a long-dose-interval hypothesis. Patient data come next.](https://chinapharmadesk.com/zai-zl1503-phase1-dosing-evidence.md) - Zai Lab (NASDAQ: ZLAB; HKEX: 09688) reported ZL-1503 Phase 1 healthy-volunteer data on November 13. Trial NCT07235384 moves the IL-13/IL-31R alpha bispecific toward patient readouts. - [Cebranopadol's U.S. NDA advances Conba's licensed asset, within defined China rights](https://chinapharmadesk.com/conba-cebranopadol-us-nda-rights.md) - Zhejiang CONBA Pharmaceutical (SSE: 600572) disclosed Adneuris' U.S. NDA submission for cebranopadol on November 14; its July licence covers acute pain in Greater China. - [China’s regulator wires the plumbing for BD trial handoffs and segmented ADC manufacturing—with two sharp catches](https://chinapharmadesk.com/china-nmpa-sponsor-transfer-segmented-manufacturing.md) - On Nov 13, 2026, China's NMPA and CDE issued Order No. 828 rules on 20-day clinical sponsor transfers, API holder transfers and segmented ADC manufacturing—adding single-NDA and inbound-only gates. - [Zhaoke clears once-nightly cyclosporine dry-eye gel in China—three years after a withdrawn NDA and too late for 2026 NRDL](https://chinapharmadesk.com/zhaoke-cyclosporine-gel-china-dry-eye-approval.md) - Zhaoke Ophthalmology (06622.HK) won China NMPA approval on Nov 10 for once-nightly Cyclosporine Ophthalmic Gel (Jingyouling) after Phase 3 COSMO, facing a self-pay 2027 race against Xingqi (300573.SZ). - [Evopoint wins first China drug approval for ICU pneumonia antibiotic funobactam two months after STAR Market IPO](https://chinapharmadesk.com/evopoint-funobactam-china-pneumonia-approval.md) - Suzhou Evopoint Biosciences (688837.SS) won China NMPA approval for Class 1 antibiotic imipenem-cilastatin-funobactam (Funuokai, XNW4107) in adult HABP/VABP after Phase 3 REITAB-2 (NCT05204563). - [TenNor buys a seven-month reprieve from Grand Life Science as CDE review pushes H. pylori drug past year-end](https://chinapharmadesk.com/tennor-rifasutenizol-grand-life-deadline-extension.md) - TenNor Therapeutics (06872.HK) and Grand Life Science extended the China approval termination deadline on H. pylori drug rifasutenizol (TNP-2198) from Dec 31, 2026 to July 31, 2027 after a CDE supplement. - [Hansoh commits up to RMB 317m to Hong Kong’s AilsynBio for AI-designed oral cyclic peptides](https://chinapharmadesk.com/hansoh-ailsynbio-ai-oral-cyclic-peptide-deal.md) - Hansoh Pharmaceutical (03692.HK) licensed Hong Kong-based AilsynBio's AI platform on Nov 13 to discover oral cyclic peptides, paying up to RMB 317m ($44.0m) plus royalties and taking program IP. - [RemeGen feeds a second BAFF/APRIL drug into Vor Bio—mostly for warrants, not cash](https://chinapharmadesk.com/remegen-vor-bio-rc298-license.md) - RemeGen (09995.HK / 688331.SS) added preclinical BAFF/APRIL inhibitor RC298 to its Vor Bio (NASDAQ: VOR) license for $10m cash, $46m in warrants (9.99% cap) and up to $300m dev milestones. - [From double-licensing lawsuits to a 48% price cut: how Qilu repriced its TYK stake](https://chinapharmadesk.com/tyk-qilu-repriced-hshare-placement.md) - Tracing 20 months of HKEX filings behind TYK Medicines' (02410.HK) HK$288.8m H-share placement at HK$3.80: from disputed 2025 Huiyu agency talks and RMB 300m settlement to Qilu's 48% repriced buy-in. - [Qilu registers a Phase 3 myeloma trial for its BCMA/GPRC5D trispecific—against triplets, not bispecifics](https://chinapharmadesk.com/qilu-qls4131-myeloma-phase3.md) - Qilu Pharmaceutical posted a 300-patient Phase 3 myeloma study (NCT07933432) for GPRC5D/BCMA/CD3 trispecific QLS4131 vs. DPd or PVd triplets, trailing J&J's ramantamig and Innovent's IBI3003. - [China's revised BE filing rules put study design and trial history in focus](https://chinapharmadesk.com/china-cde-be-filing-rules.md) - CDE Notice No. 51 of 2026 revises China's bioequivalence (BE) filing procedure effective Feb 1, 2027, reshaping CRO study routing, batch traceability and CTD 2.7.1 trial-history duties. - [Ribo files EU trial application for dual-target lipid siRNA SR122](https://chinapharmadesk.com/ribo-sr122-dual-sirna-eu-cta.md) - Suzhou Ribo Life Science and Ribocure filed an EU Phase 1 CTA on Nov 10 for dual-target GalNAc siRNA SR122 (ApoC3/PCSK9), alongside Phase 2 RBD5044. Authorization and human data remain ahead. - [Hengrui gains China approval for ANGPTL3 antibody in rare cholesterol disorder](https://chinapharmadesk.com/hengrui-shr1918-angptl3-china-approval.md) - Jiangsu Hengrui (600276.SS) subsidiary Suncadia won China NMPA approval for ANGPTL3 antibody SHR-1918 in HoFH patients aged 12+. Launch timing, pricing and NRDL status remain ahead. - [China’s next drug-price reset runs on provincial clocks](https://chinapharmadesk.com/china-12th-vbp-provincial-calendars.md) - Fujian and Beijing rollout notices for China’s 12th national VBP drug tender show separate price, hospital procurement and NHSA 70% payment-standard switches. - [China's new drug rules target the gap between insurance and hospital access](https://chinapharmadesk.com/china-class1-hospital-formulary-policy.md) - Four-agency Notice No. 18 of 2026 links hospital access with payment review and safe use. NHSA Notice No. 29 adds the 2027 implementation calendar and broader negotiated-drug support. - [BrightGene reports a Phase 3 glucose-control edge over semaglutide 1 mg](https://chinapharmadesk.com/brightgene-bgm0504-diabetes-phase3.md) - BrightGene (688166.SS) reported a 32-week Phase 3 HbA1c advantage for GLP-1/GIP agonist BGM0504 10 mg over semaglutide 1 mg (NCT06716216). NDA filing and approval remain ahead. - [Charles River’s $470m Frontage purchase hinges on a take-private and a split](https://chinapharmadesk.com/charles-river-frontage-470m-split.md) - Charles River (CRL) plans a $470m purchase of Frontage (01521.HK) target CRO operations via a take-private and split with Tigermed (300347.SZ / 03347.HK) and Song Li. - [Qilu registered a Phase 3 for its Claudin6 ADC. The trial has not started.](https://chinapharmadesk.com/qilu-qls5132-cldn6-adc-phase3.md) - Qilu Pharmaceutical registered a 420-patient Phase 3 ovarian cancer trial (NCT07926048) for Claudin6 ADC QLS5132; ClinicalTrials.gov still lists the study as not yet recruiting. - [Haisco opened a China Phase 3 for an oral IL-23. The category leader is already a pill.](https://chinapharmadesk.com/haisco-hsk47388-oral-il23-phase3.md) - Haisco (002653.SZ) registered a 390-patient China Phase 3 psoriasis trial for oral IL-23 tablet HSK47388, entering a category where J&J’s oral icotrokinra is already approved. - [TYK is paying RMB 300 million so Qilu can sell a drug Huiyu says it already had.](https://chinapharmadesk.com/tyk-ty9591-huiyu-qilu-settlement.md) - TYK Medicines (02410.HK) plans to pay Huiyu (688553.SS) RMB 300m—matching Qilu Pharmaceutical’s upfront—to clear mainland China commercial rights for EGFR drug TY-9591. - [China cleared Lilly’s weight-loss pill a week after CIIE. The BMI line stayed American.](https://chinapharmadesk.com/lilly-orforglipron-china-bmi-label.md) - NMPA approved Eli Lilly’s oral GLP-1 orforglipron (Muyouda) for adult weight loss at Western BMI 27/30 thresholds, whereas Novo Nordisk’s China injection label uses BMI 24/28. - [Reading China’s TGCT market through Beijiemai: hospitals first, reimbursement still open](https://chinapharmadesk.com/abbisko-beijiemai-china-hospital-access.md) - China approved Abbisko’s CSF-1R inhibitor Beijiemai (pimicotinib, 02256.HK) first and Merck KGaA launched in tertiary hospitals, while list price and NRDL status remain open. - [Abbisko’s pimicotinib at FDA: reading the China-to-Merck path](https://chinapharmadesk.com/abbisko-pimicotinib-merck-deal-path.md) - Abbisko (02256.HK) won FDA approval for CSF-1R inhibitor pimicotinib (PIMJETMI, NCT05804045) in TGCT; Merck KGaA holds global rights under a $70m upfront, $85m option and $605.5m deal. - [Yili Pharma raises nearly RMB 400m Series A for radiopharma](https://chinapharmadesk.com/yili-pharma-radiopharma-series-a.md) - China radiopharma developer Yili Pharma closed a nearly RMB 400m Series A co-led by Huagai Capital and Kangjun Capital, with CSPC-linked backing, to advance theranostic candidates. - [HighField’s TLL-018 tops tofacitinib on ACR50 in Phase 3 RA](https://chinapharmadesk.com/highfield-tll018-ra-phase3.md) - HighField Biopharmaceuticals reported ACR 2026 Phase 3 TARA data for JAK1/TYK2 inhibitor ginoxitinib (TLL-018): 73.0% week-24 ACR50 vs 49.5% for tofacitinib in rheumatoid arthritis. - [AASLD 2026: MASH strategies split between GLP-1s and liver-fat siRNA](https://chinapharmadesk.com/aasld-mash-glp1-sirna-split.md) - AASLD 2026 MASH updates span Boehringer’s survodutide, Novo’s semaglutide, and Regeneron/Alnylam’s siRNA ALN-CIDEB (~70% liver-fat reduction), splitting metabolic and liver-knockdown paths. - [Abbisko’s pimicotinib wins FDA approval for TGCT](https://chinapharmadesk.com/abbisko-pimicotinib-fda-approval.md) - FDA approved Abbisko (02256.HK) and Merck KGaA’s CSF-1R inhibitor pimicotinib (PIMJETMI / Beijiemai, NCT05804045) for adult TGCT after NMPA, Canada and Switzerland clearances. ## Optional - [RSS Feed](https://chinapharmadesk.com/rss/) - [Sitemap](https://chinapharmadesk.com/sitemap.xml) - [Full content of pages and posts](https://chinapharmadesk.com/llms-full.txt)